Medmira (TSE:MIR) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MedMira Inc. has reported progress in expanding its market presence and securing regulatory approvals. The company received FDA approval for its HIV test and is awaiting further approvals for its Syphilis test in Canada. Additionally, MedMira has signed significant distribution agreements in the US to enhance its product reach.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.